Luke Hammond is Director of Quantitative Imaging in the Department of Neurology at The Ohio State University. He is an imaging scientist working at the interface of microscopy, quantitative image analysis, and biology, with more than two decades of experience in advanced microscopy for neuroscience and cell biology. His expertise includes establishing and leading advanced imaging platforms that support interdisciplinary biomedical research.
From 2008 to 2017, he led the Advanced Microscopy Facility at the Queensland Brain Institute, a leading neuroscience research institute at The University of Queensland in Australia. He was subsequently recruited to Columbia University in New York, where he helped establish the Cellular Imaging Platform at the Zuckerman Mind Brain Behavior Institute, Columbia's interdisciplinary neuroscience institute focused on understanding the brain, mind, and behavior, and served as Director of Cellular Imaging. He joined The Ohio State University in 2023.
A major focus of his work has been the development of accessible, reproducible software tools for quantitative biological imaging. His software contributions include OBCOL, a 3D organelle-based colocalization method developed during his early work on protein trafficking at the Institute for Molecular Bioscience; BrainJ and SpinalJ, Fiji-based pipelines for whole-brain and spinal-cord reconstruction and analysis developed at Columbia; and RESPAN, an open-source deep-learning pipeline for neuron and dendrite restoration, segmentation, and analysis. His current work includes developing QLEAN, a quantitative imaging and analysis framework for studying interactions among immune cells, non-neuronal cells, and sensory neurons in the local tissue microenvironment.
At Ohio State, his group builds on this platform- and software-development experience to develop new quantitative imaging methods for complex biological datasets. The group integrates advanced microscopy, image analysis, and computational workflows to study neuroimmune interactions, chemotherapy-induced toxicity, and axon regeneration. He currently serves as Co-Investigator on NIH-funded projects examining damage-associated molecular patterns in chemotherapy-induced toxicity and immune-cell contributions to skin reinnervation after peripheral nerve injury.